All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Cilta-cel Maintains Survival Benefit in Lenalidomide-Refractory Multiple Myeloma

October 23rd 2024

Binod Dhakal, MD, MS, discusses updated survival data from the CARTITUDE-4 trial of cilta-cel in pretreated, lenalidomide-refractory multiple myeloma.

Adolescents/Young Adults With Cancer Experience Increased Financial Toxicity, Unmet Social Needs

October 23rd 2024

Routine screening revealed high financial toxicity and unmet social needs among adolescent and young adults with cancer.

SC Daratumumab Plus VRd Earns EU Approval in Newly Diagnosed, Transplant-Eligible Myeloma

October 23rd 2024

The European Commission has approved daratumumab plus bortezomib, lenalidomide, and dexamethasone in ASCT-eligible, newly diagnosed multiple myeloma.

Fadraciclib Demonstrates Safety, Early Efficacy Signals in CDKN2A/B+ Advanced Solid Tumors

October 23rd 2024

Fadraciclib was safe and showed signs of efficacy in advanced solid tumors harboring CDKN2A/B alterations.

ADCs Redefine HER2+ NSCLC Landscape With Potential to Shift to the Frontline Setting

October 23rd 2024

Noman Ashraf, MD, discusses data with T-DXd in HER2-mutated and -overexpressing lung cancer populations and next steps with ADC combination therapies.

Clinical Trial Education Is Essential in Hematology and Oncology Fellowship Curricula

October 23rd 2024

Many early-career clinicians are not familiarized with clinical trials during their training, so the opportunity to educate future trialists is hindered.

First-in-Class Bicycle Toxin Conjugate Targeting Nectin-4 Generates Excitement in Urothelial Carcinoma

October 23rd 2024

Oncologists detail how zelenectide pevedotin, which is under evaluation in the Duravelo-2 trial, could fill an unmet need in metastatic urothelial carcinoma.

NX-5948 Generates Responses in R/R Waldenström Macroglobulinemia

October 22nd 2024

Treatment with the BTK degrader NX-5948 led to responses in patients with relapsed/refractory Waldenström macroglobulinemia.

FDA Approves Companion Diagnostic for Zolbetuximab in CLDN18.2+ Gastric/GEJ Cancer

October 22nd 2024

The FDA has approved the Ventana CLDN18 (43-14A) RxDx Assay as a companion diagnostic for zolbetuximab in CLDN18.2-positive gastric/GEJ cancer.

Individualized Bosutinib Dose Adjustments Lend a Manageable AE Profile in Pretreated CML

October 22nd 2024

Jorge Cortes, MD, discusses findings with bosutinib in CML and the importance of dose adjustment as a strategy for managing bosutinib-related AEs.

Acalabrutinib Plus Venetoclax/Rituximab Yields 100% ORR in Treatment-Naive Mantle Cell Lymphoma

October 22nd 2024

Acalabrutinib plus venetoclax and rituximab generated a 100% response rate in treatment-naive mantle cell lymphoma.

ONCT-534 Reduces PSA Levels, Is Tolerable in Relapsed/Refractory mCRPC

October 22nd 2024

ONCT-534 reduced prostate-specific antigen levels in patients with relapsed/refractory metastatic castration-resistant prostate cancer.

TG4001 Plus Avelumab Fails to Boost PFS in Recurrent/Metastatic, HPV16+ Cervical, Anogenital Tumors

October 22nd 2024

The addition of TG4001 to avelumab failed to improve progression-free survival in HPV16-positive cervical and anogenital tumors.

Review Shows Discrepancies in Narcotics Prescription Trends for Cancer Pain Management

October 22nd 2024

Pain management specialists are rarely consulted to help assess pain in patients with cancer, leading oncologists to often prescribe narcotics.

The Importance of Hematology/Medical Oncology Fellowship

October 22nd 2024

Samuel A. Kareff, MD, MPH, shares his reflections on the benefits, challenges, and critical elements of effective mentorship in hematology/oncology.

New Data Shed Light on the Efficacy of BTK Inhibitors in the CLL Treatment Paradigm

October 21st 2024

David C. Fisher, MD, discusses the evolving role of BTK inhibitors in the CLL treatment paradigm.

Telisotuzumab Adizutecan Represents a Novel c-Met–Targeting ADC in MET-Amplified CRC

October 21st 2024

John H. Strickler, MD, highlights the mechanism of action of telisotuzumab adizutecan and the rationale for targeting c-Met in colorectal cancer.

Markman’s Take: Vibostolimab in dMMR Endometrial Cancer, Adjuvant Chemo in Cervical Cancer, and More

October 21st 2024

For more first-hand insights, head over to our YouTube channel to watch Dr Markman discuss the inner workings of oncology: https://rb.gy/bvumdn.

Frontline Tislelizumab/Chemo Approaches EU Approval for Gastric/GEJ Adenocarcinoma and ESCC

October 21st 2024

The European Medicines Agency has recommended extended authorization for frontline tislelizumab plus chemotherapy for GEJ adenocarcinoma and ESCC.

FDA Accepts NDA Resubmission for First-Line Rivoceranib/Camrelizumab Combo in Unresectable HCC

October 21st 2024

The FDA has accepted the new drug application resubmission for the first-line combination of rivoceranib plus camrelizumab in unresectable HCC.